The Functional Genomics Centre, a joint Cancer Research Horizons-AstraZeneca facility on the Cambridge Biomedical Campus, delivers advanced CRISPR-based screening for cancer drug target discovery and validation.
This state-of-the-art lab supports large-scale genetic screens to prioritise oncology targets, enhancing the drug discovery pipeline with cutting-edge genomic technologies.
The Cambridge site at the Milner Therapeutics Institute emphasises functional genomics, target discovery, and therapeutics development through academic-industry alliances. It hosted the initial Functional Genomics Centre operations.
Key focus on pooled CRISPR screens to validate new drug targets, bridging discovery science with translational applications in oncology.
The Glasgow site at the CRUK Scotland Institute is a key drug discovery hub specialising in small molecule chemistry, biology, and translational research for cancer therapeutics. It employs over 30 scientists focusing on novel targets and compounds.
The site leverages the legacy of the Cancer Research UK Beatson Institute to advance projects like multivariant Ras inhibitors, contributing to Cancer Research Horizons' mission of accelerating drug discovery.
The London Headquarters of Cancer Research Horizons serves as the central hub for strategic planning, commercialisation, and coordination of drug discovery efforts across the UK. It focuses on translating breakthrough cancer research into new treatments through partnerships with industry and academia.
This site oversees the overall portfolio of over 90 start-ups and 14 new cancer drugs brought to market. Key activities include expert network coordination, funding allocation, and advancing oncology innovations from lab to clinic.
The Newcastle site, hosted at Newcastle University, specialises in fragment-based drug discovery, structural biology, and cross-sector collaborations for oncology therapeutics. It benefits from partnerships like with Astex Pharmaceuticals.
This site utilises Diamond Light Source for synchrotron-based screening, focusing on challenging cancer targets and advancing candidates towards clinical development.
